i agree with everything you said about amgen.ye in this country in terms of innovation. but that's going to be the argument. that there's something called a fair price that isn't reflected when you have 17-year patent protection and the company benefits -- and also, kevin. you look at the pharmaceutical industry. they get a patent then do extended release. spend hundreds of millions of dollars to get new patent protection to extend it. >> i'm not going to defend every single thing that every company does to in some cases gain the patent system. we could probably agree on some of the details. but i think in the main, a strong patent protection system is central to the system. and amgen was centrally involved in trying to strengthen the patent law and i'm proud of what we did. the tech industry wanted to weaken patents and we thought that patents really, really mattered. and in countries that don't have patents, innovation doesn't happen. >> zero. >> is it perfect? no, it's not perfect. but in the main, i think the experience of am

but amgen is incredibly cheap too. i prefer amgen over gilead only because gilead has got to get off the schneid and start buying something with that money. they should have been buying some of the companies we talk about all the time on this show. they could make money. but at least they could watch the show. ray in illinois. ray. >> caller: hi, jim. my question is on monsanto. it was selling at about $108 prior to the offer that bayer gave it for $128. after that offer, the price went down to $103. my question is why would it go down to $103, and then would you expect to recover as you get closer to the buy out date? bears. it could go 0-3 and no one makes the playoffs. this company is -- this deal is not to be believed, and i've been saying that from the moment it was asked because the farmers will not let it happen. take it from me. monsanto is not going to be able to close that deal, and i wish i were being an advisor in that room. i don't want any money. i would just tell them stop wasting our time. don't be fool

and amgen the top holding in ibb.t against a 283 stop, so close enough to where guy is 285. >> more at the full show, 5:30 p.m. eastern time on friday. up next, final trade. stay tuned. hey gary, what are you doing? oh hey john, i'm connecting our brains so we can share our amazing trading knowledge. that's a great idea, but why don't you just go to thinkorswim's chat rooms where you can share strategies, ideas, even actual trades with market professionals and thousands of other traders? i know. your brain told my brain before you told my face. mmm, blueberry? tap into the knowledge of other traders on thinkorswim. only at td ameritrade. we're drowning in information. where, in all of this, is the stuff that matters? the stakes are so high, your finances, your future. how do you solve this? you don't. you partner with a firm that advises governments and the fortune 500, and, can deliver insight person to person, on what matters to you. morgan stanley. they said a bottle was just a bottle. that no one would ever notice

amgen has a couple of key catalysts coming on friday. be out on sunday and it could be helping those shares. the company did release positive news on a stage three study around crohn's disease. we do have strength in the biotech, but the big boost for the nasdaq overall is by far apple. there was research out with bullish comments this morning. the team was kind enough to speak with us on the phone. this include steve and john donovan. they say the samsung note seven fiasco creates "a gift wrapped opportunity for apple." they have raised the firm's iphone unit estimates for the rest of the year, taking the december quarter numbers up above consensus. is team says that the stock likely to continue rising into the all important iphone seven or iphone 10 year anniversary coming up next year. vonnie: lots of strength down at the nasdaq, but there was a big selloff on friday. could you see more selling ahead? abigail: when we take a look at a relatively near-term and a six-month chart of the nasdaq, and mrs. g #btv 439. the nasdaq did break a

amgen is the seventh biggest shipping firm. byis being hampered overcapacity on freight carriers. have for years been debating the question of when a taxi driver decides to calls -- do they work more than it is busy or simple go home? thanks to uber, there is a new flood of information on the the ridesharing from finding less experienced drivers tended to work toward a daily revenue goal. the more experienced drivers were more likely to work when there was reasonable demand. annette: that is very interesting. uber has completely revolutionized the whole of the taxi industry. thank you so much, stephen carroll, with today's business news. coming up, the press review. time now to take a look at what is making headlines around the world. i'm joined in the studio by catherine viette. most prize that the german media has been reporting on that shocking defeat of angela merkel's christian democratic party. toherine: we will go right derek and its front-page headline is, "the cdu overtaken by the right, afd in second place." if we stay on the front page, their reporting that after the el

but amgen, amgen has a drug that i thought would have done better.wn, but you'll see kite up and i think that this is just one of those situations where there's just great science being done on immunotherapy. what we ought to be focused on is the endless number of underwritings. they issued millions of units. rice buys vantage, that's marcellus natural gas. they sell 40 million shares. this remains a theme coming right to the market. nor dick american tankers completely pans every single shareholder and issues 11 million shares. i don't know, there's a lot of equequity being offered and it' in these particular areas. >> the dow is not doing a whole lot although the ten-year is down. let's get over to dominic chu. >> you hit a lot of those points and we want to emphasize the ten-year yields at 1.55%. they are at least giving a little bit of pauop and strengt to certain parts of the market. remember, we are -- now we're positive, 25 points to the upside for the dow. nasdaq showing 12 points and the s&p up about 2. the leaders so far in early trading ha

on the flipside, amgen's cancer drug did not show superiority over competing drugs by decatur pharmaceuticalsthat was in a trial in a treatment for multiple myeloma. are down ashares well. a downgrade on that stock. the hepatitis b forecasts have turned out right bearish. a little bit of strength, a little bit of weakness in biotech. mark: 3:19 in london, 10:19 in new york. still ahead, pressure building on deutsche bank and commerce bank. -- commerzbank. ♪ vonnie: you are watching "bloomberg markets." mark: 10:21 in new york. es taking center stage. deutsche bank, commerzbank, credit suisse -- all in the red today. new concerns with european finance team leader simone meier. commerzbank,ith speculation mounting about the sorts of cuts we are going to get him commerzbank asap. 9000 jobs is the latest figure. it is going to be pretty big, whatever it is, it seems. onone: with the focus deutsche bank, people forget there is another large german lender under enormous pressure to cut costs. commerzbank has been looking at ways to reduce costs for a while . they have a new ceo who came in in may.

we like amgen and medtronnic. medtronnic is a superior name in the space. we are adding to our holdings in both today and have been over the last few weeks. we really like the space despite political head winds and the normal worries over fa pharmaceutic pharmaceuticals. we like this stock very much. >> very good. folks, thank you all for joining us today. we'll let you get to all that is going to happen over the next hour here. we will be standing aside as everybody is running past us on the trading floor. the other thing, there is a rebalancing coming and a creation of an 11th sector inside the s&p 500. the real estate investment trust. >> odd number. they have to come up with it pretty soon. 49 minutes left in the trading session. the dow is down about 100 points. going into today the dow was up 120 plus points. we are almost break even for the week. >> we have been talking about this big story. the justice department wanting $14 billion from deutsche bank to settle toxic mortgage securities claims. deutsche bank says no way. we will tell you what the an

. >> i like amgen. >> okay. >> gilead is cheap. have to do an m & a. a big deal and doesn't seem to be coming. >> cheaper all the time. >>> jon najarian couldn't stay away. while he'll join us live from the pits in chicago. unusual activity today and it's in a security company. >>> plus, retail is moving lower. number of big stocks are in the red. there's a look at the board. other bargains. on that board. talk about it, next. >>> announcer: "halftime report" with scott wapner is "the" place for market-moving interviews. >> you don't call a company a sewer because the company made a mistake. >> announcer: real money -- >> we are short both tesla and solar city. >> announcer: -- real debates. >> people think that globalization has hurt businesses. it's not. it is technology that's hurt businesses. >> competition is a good thing. i don't want to go back to a single marketplace. >> announcer: the most profitable hour of the trading day. >> i love this show! all i do is get to tweet about this show! i'm on the show. this is like the greatest moment of my l

i amgen winly outraged at this guy. >> you feel like most of the crowd did last night in san diego.ial media, he has been condemned. now, the unfortunate thing and the disappointing thing about all of this is it's now spilled into sports. and now in sports we have to deal with domestic violence. we have to deal with drugs. we have child abuse. and now we're having a racial divide. it used to be the two places where america knew they could get along and come together was in team sports and in the military. and now that divide is not -- is widening, and it's now spreading into sports, and it's very disappointing. >> i'm not going to force you into an opinion on kaepernick here. here's what i'm going to ask you, though. so the guys wear socks that depict police officers as pigs. remember that? and he kneels during the singing of the national anthem by an african-american military member. is he going to lose endorsements because of this? >> of course he is. i think wearing those socks is despicable. i don't like it a bit. now, you know, the nfl, though, i blame the policy in the nfl. th

. >> i would push back and ask, what do you make of the amgen data, very similar to pfizer.buying one major drug. but sometimes these things really don't work out and you end up paying $9 billion for them. >> i get -- i look at it as a sentiment sort of structure where you look at people have been super frustrated. the stock is down $78 a share. i mean, it's gotten to a point where a value investor should step in and buy the stock. they breathe acquisition. it's $100, in my opinion. it's going to -- >> i've got one for you. sorry to jump in. what about valuiant? this is a $9 billion market cap. >> gilead bought valiant, would go higher? you think it would reverse the 20% decline? >> it is $100 billion company with $30 billion expected sales in a $9 billion market cap. i was going to get there. what i'm saying is, you know -- >> laughing at you. >> i'm laughing with him. but i'm laughing. >> so diplomatic. that meg terrill. >> somebody is going to buy valiant. >> somebody. >> but it's going to cost more than what you're projecting it to be right now, just based upon the debt,

amgen in particular is second behind apple on the nasdaq.bloomberg he thinks a couple of key catalysts could be driving the stock higher this week when they release clinical data on a headache drug. on sunday, they released data on an osteoporosis drug. mixed signals in biotech. we take a look at the bloomberg. we see that the biotech index is trying to reverse the long downtrend. do that toing to some degree, but on recent weakness, it is stuck in a near-term range, suggesting we could see it trade back down toward the range in yellow. needed or ifion is we are going to see a little bit of a downturn or continuation, i should say, of what happened on friday. scarlet: that is the theme not just for the nasdaq, but for the market at large. abigail doolittle, thank you so much. matt: you could say he is a doctor of deals. he has been behind some of the largest m&a transactions of all time. interviewusive earlier this week, bloomberg's executive editor of global deals asked how dealmaking -- him how dealmaking has been since the u.k. voted to l

there was a move by amgen to lock up exclusivity of rights, maybe it hurt other players. this stuff was there. also general support in the public, according to a recent survey of some kind of drug control pricing. i do think that's something that's at least an overhang on the group. >> we have time for a yes or no. >> it's politics. >> exactly. >> thanks for joining us. what a day here on "closing bell." "fast money" begins right now. >>> "fast money" starts right now. overlooking new york city's times square. i'm melissa lee. tonight on "fast," stocks getting hammered today. so is wall street's biggest bull, tom lee, used the occasion to buy the dip. plus congress giving it to wells fargo ceo john stumpf on the hill today, but they had no problem taking his money. we'll tell you which representative took the most from the embattled

to 1:00 amgen. whose idea was 1:00 a.m. ram, was that yours? it was ralph.lready there in "farmville" as we speak. we'll have more after this. .. stuart: stocks continuing to rally and hope of a rescue and easier punishment from deutsche bank and maybe they are joined at the hip. we have been busy trying to penalize banks for their role in the 2008 meltdown and it was deutsche bank's turn and we were looking at a $14 billion fine and it will be whittled down dramatically which is good news for deutsche bank because if it is $14 billion that is there market worth. doesn't look like that is the case, if everything came to the brink the german government would come to the rescue, deutsche bank which is a fraction of what was trading at a month ago up appreciably today, 14%, very low levels, marketwatch's bill watts is with us. the rationale behind this event, built on a rescue or easier punishment for financial institutions but at its core is a hope for help from somebody. don't know if we should be celebrating that but what do you think? >> $14 billion number

. >> richard evans has said that both amgen could be exposed here, as well. a lot of focus on some players in the industry. i wonder who is most exposed to this kind of development. >> a lot of companies have taken more than 10% price increases every year. maybe they do it in a couple different increments. they do it at smaller increases but twice a year. a lot of companies could be at risk of being focussed on here. one analyst asked is this implicit endorsement of 9.5% is okay. just not 10%. that is what brent saunders pledged to do, not raise more than 10%. >> 9.996. >> that would be a source of gravity for where pricing would go. that is one complication in trying to set very specific bright lines and also making somewhat subjective evaluations. >> heather brash will be heading to the hill next week. see what she has to say in defense of her decisions. >>> up next, cbs delaying launch of "star trek" tv show until may. ys, at's happening here? hey nico, this is w alert syem but thinkorswim aly lets youe m. create custom alerts for l the ings that are impor